Shrenik Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.74 Cr
- Company Age 43 Year, 9 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 1.29 M
- Revenue Growth 60.82%
- Profit Growth 348.38%
- Ebitda 771.14%
- Net Worth 6.59%
- Total Assets 16.01%
About Shrenik Pharma
Shrenik Pharma Pvt Ltd (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 April 1981 and has a history of 43 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.74 Cr.
The company currently has active open charges totaling ₹1.29 M.
Lav Vadehra and Vishnu Gurav serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1981PTC024323
-
Company No.
024323
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Apr 1981
-
Date of AGM
30 Sep 2017
-
Date of Balance Sheet
31 Mar 2017
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Shrenik Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lav Vadehra
|
Director | 01-Apr-1985 | Current |
|
Vishnu Gurav
|
Director | 10-Jun-1997 | Current |
Financial Performance of Shrenik Pharma.
Shrenik Pharma Pvt Ltd, for the financial year ended 2017, experienced significant growth in revenue, with a 60.82% increase. The company also saw a substantial improvement in profitability, with a 348.38% increase in profit. The company's net worth moved up by a moderate rise of 6.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shrenik Pharma?
In 2017, Shrenik Pharma had a promoter holding of 59.67% and a public holding of 40.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Syglak Laboratories Private LimitedLav Vadehra is a mutual person
-
Eastland Exports Company Private Limited
Lav Vadehra is a mutual person
-
Glazers Exports (India) Pvt Ltd
Lav Vadehra is a mutual person
Charges (Loans)
₹0.13 Cr
₹0
Charges Breakdown by Lending Institutions
- The Maharashtra State Financial Corporation : 0.13 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Mar 1982 | The Maharashtra State Financial Corporation | ₹1.29 M | Open |
How Many Employees Work at Shrenik Pharma?
Shrenik Pharma has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shrenik Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shrenik Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
